Predictors for the combined primary outcome were history of COPD, use of vitamin-K antagonist, concomitant heart failure, reflected by mineralocorticoid receptor antagonists use, lower sodium and higher urea and (log-)NT-proBNP levels, lower AV mean gradient and larger LVOT diameter (area under the curve (AUC): 0.74 (internal validation: 0.72 and external validation: 0.66)).<h4>Conclusion</h4>Our externally validated model can reasonably identify patients with both poor symptom improvement and adverse events after TAVI. The gene discussed is NR3C2; the disease is heart failure.